Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sézary syndrome: a systematic review.

MLA

Stewart, Jacob R., et al. “Alemtuzumab Is an Effective Third-Line Treatment versus Single-Agent Gemcitabine or Pralatrexate for Refractory Sézary Syndrome: A Systematic Review.” European Journal of Dermatology : EJD, vol. 28, no. 6, Dec. 2018, pp. 764–74. EBSCOhost, https://doi.org/10.1684/ejd.2018.3444.

APA

Stewart, J. R., Desai, N., Rizvi, S., Zhu, H., & Goff, H. W. (2018). Alemtuzumab is an effective third-line treatment versus single-agent gemcitabine or pralatrexate for refractory Sézary syndrome: a systematic review. European Journal of Dermatology : EJD, 28(6), 764–774. https://doi.org/10.1684/ejd.2018.3444

Chicago

Stewart, Jacob R, Neil Desai, Syed Rizvi, Hong Zhu, and Heather W Goff. 2018. “Alemtuzumab Is an Effective Third-Line Treatment versus Single-Agent Gemcitabine or Pralatrexate for Refractory Sézary Syndrome: A Systematic Review.” European Journal of Dermatology : EJD 28 (6): 764–74. doi:10.1684/ejd.2018.3444.